image: Empowering the future of aging research: Maxwell Biosciences to sponsor ARDD 2025, the world's largest conference on aging research in the biopharmaceutical industry
Credit: Aging Research and Drug Discovery
COPENHAGEN, Denmark, March 3, 2025—The University of Copenhagen is excited to announce Maxwell Biosciences as Tier 1 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen and online.
“We are honored to sponsor ARDD 2025, the world’s top gathering uniting leading minds in aging research and drug discovery. Our mission to develop CLAROMER™ technology—synthetic molecules that enhance the innate immune system—aligns seamlessly with the conference's focus on extending healthspan and combating age-related diseases. We look forward to engaging with fellow pioneers to advance solutions that promote healthy longevity.” said Joshua "Scotch" McClure from Maxwell Biosciences.
ARDD has grown to become the largest and most important conference in longevity biotechnology. Each year, ARDD brings together a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians and related health care professionals to discuss the latest advancements in aging research. The event provides unique opportunities to connect with brilliant minds, fostering collaboration and showcasing groundbreaking research in the field.
“We are extremely honored to host Professors Meldal and Levitt at ARDD 2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modelling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference,” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.
“We are really excited for ARDD 2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their groundbreaking contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience,” said Daniela Bakula, Ph.D., University of Copenhagen.
“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world,” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine.
“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches,” said Prof. Dr. Evelyne Bischof, the organizer of the Longevity Medicine Days.
Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.
About Aging Research for Drug Discovery Conference
At ARDD, leaders in the aging, longevity and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest is to extend the healthy lifespan of everyone on the planet.
For further information, images or interviews, please contact:
ardd@pharma.ai
About Maxwell Biosciences
Founded in 2016, Maxwell Biosciences is a preclinical drug platform company that develops ClaromersTM, synthetic small molecules that mimic and improve upon the natural immune system. Inspired by nature, these deep tech breakthrough molecules have been shown to be effective against Ebola, zika, herpes, dengue, pan-coronavirus and pan-influenza A (avian, swine and human) in destroying viruses, but also all tested bacteria, fungi and biofilms with a single compound, while safely preserving healthy cells. This new "One Drug for Many Bugs" technology has been shown to be well-tolerated in lab-grown human tissue and in multiple animal studies and is shelf-stable. The compounds imitate key components of the innate immune system: humanity's greatest asset in fighting disease. Maxwell's technology is protected by numerous granted and pending patents and is led by a world-class team of scientists, military veterans and experienced life science executives.
For more information, visit MaxwellBiosciences.com, or follow us on X and LinkedIn.
Maxwell Biosciences Media
press@maxwellbiosciences.com
Maxwell Biosciences Investors
investor.relations@maxwellbiosciences.com